Skip to content

Study · Animal study (in vivo) · rabbit and sheep · 2012

8 results

Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide.

Kloner RA, Hale SL, Dai W, Gorman RC, Shuto T, Koomalsingh KJ, Gorman JH 3rd, Sloan RC, Frasier CR, Watson CA, Bostian PA, Kypson AP, Brown DA

Journal of the American Heart Association22 Jun 2012Cited by 128 (Europe PMC)

PMID23130143 (opens in a new tab)PMCIDPMC3487333 (opens in a new tab)DOI10.1161/jaha.112.001644 (opens in a new tab)PepBankPUB-23130143
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

BackgroundManifestations of reperfusion injury include myocyte death leading to infarction, contractile dysfunction, and vascular injury characterized by the "no-reflow" phenomenon. Mitochondria-produced reactive oxygen species are believed to be centrally involved in each of these aspects of reperfusion injury, although currently no therapies reduce reperfusion injury by targeting mitochondria specifically.Methods and resultsWe investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models. Postischemic administration of Bendavia reduced infarct size in an in vivo sheep model by 15% (P=0.02) and in an ex vivo guinea pig model by 38% to 42% (P<0.05). In an in vivo rabbit model, the extent of coronary no-reflow was assessed with Thioflavin S staining and was significantly smaller in the Bendavia group for any given ischemic risk area than in the control group (P=0.0085). Myocardial uptake of Bendavia was ≈25% per minute, and uptake remained consistent throughout reperfusion. Postischemic recovery of cardiac hemodynamics was not influenced by Bendavia in any of the models studied. Isolated myocytes exposed to hypoxia/reoxygenation showed improved survival when treated with Bendavia. This protection appeared to be mediated by lowered reactive oxygen species-mediated cell death during reoxygenation, associated with sustainment of mitochondrial membrane potential in Bendavia-treated myocytes.ConclusionsPostischemic administration of Bendavia protected against reperfusion injury in several distinct models of injury. These data suggest that Bendavia is a mitochondria-targeted therapy that reduces reperfusion injury by maintaining mitochondrial energetics and suppressing cellular reactive oxygen species levels. (J Am Heart Assoc. 2012;1:e001644 doi: 10.1161/JAHA.112.001644.).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an in vivo sheep model of ischemia/reperfusion, postischemic Bendavia reduced infarct size by 15%.

    In plain wordsIn sheep, Bendavia given after blood flow was restored reduced the size of heart damage by 15%.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInfarct size, in vivo sheep model
    Study

    sheepn: not reported in source

    In vivo cardiac ischemia/reperfusion
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    infarct size reduction
    15%
    sheep in vivo

    Source sentences

    Summary
    Postischemic administration of Bendavia reduced infarct size in an in vivo sheep model by 15% (P=0.02) and in an ex vivo guinea pig model by 38% to 42% (P<0.05).
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an in vivo rabbit model, the extent of coronary no-reflow was significantly smaller with Bendavia than in the control group.

    In plain wordsIn rabbits, the area of heart tissue with blocked blood flow after reperfusion was smaller with Bendavia than in controls.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCoronary no-reflow area, in vivo rabbit model
    Study

    rabbitn: not reported in source

    In vivo cardiac ischemia/reperfusion
    Comparator
    Control
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In an in vivo rabbit model, the extent of coronary no-reflow was assessed with Thioflavin S staining and was significantly smaller in the Bendavia group for any given ischemic risk area than in the control group (P=0.0085).
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    Myocardial uptake of Bendavia was about 25% per minute and stayed consistent throughout reperfusion.

    In plain wordsIn the animal heart models, heart tissue took up about 25% of Bendavia each minute, and this stayed steady during reperfusion.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableMyocardial uptake of Bendavia
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    myocardial uptake
    ≈ 25 % per minute
    reperfusion

    Source sentences

    Summary
    Myocardial uptake of Bendavia was ≈25% per minute, and uptake remained consistent throughout reperfusion.
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    Bendavia did not influence postischemic recovery of cardiac hemodynamics in any of the models studied.

    In plain wordsIn the animal heart models, Bendavia did not change how well heart function recovered after reduced blood flow.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changePostischemic recovery of cardiac hemodynamics
    Study

    n: not reported in source

    Several ischemia/reperfusion models
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Postischemic recovery of cardiac hemodynamics was not influenced by Bendavia in any of the models studied.
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  5. 05LabEx vivo tissueEfficacy outcome

    In an ex vivo guinea pig heart model of ischemia/reperfusion, postischemic Bendavia reduced infarct size by 38% to 42%.

    In plain wordsIn lab tests on guinea pig hearts, Bendavia given after blood flow was restored reduced the size of heart damage by 38% to 42%.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInfarct size, ex vivo guinea pig model
    Study

    guinea pign: not reported in source

    Ex vivo cardiac ischemia/reperfusion
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    infarct size reduction
    38 to 42%
    guinea pig ex vivo

    Source sentences

    Summary
    Postischemic administration of Bendavia reduced infarct size in an in vivo sheep model by 15% (P=0.02) and in an ex vivo guinea pig model by 38% to 42% (P<0.05).
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  6. 06LabIn vitro (cells)Efficacy outcome

    In isolated myocytes exposed to hypoxia/reoxygenation, Bendavia improved cell survival.

    In plain wordsIn cells, Bendavia improved the survival of heart muscle cells after low oxygen followed by oxygen return.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMyocyte survival after hypoxia/reoxygenation
    Study

    n: not reported in source

    Isolated myocytes
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Isolated myocytes exposed to hypoxia/reoxygenation showed improved survival when treated with Bendavia.
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  7. 07LabIn vitro (cells)Mechanism

    In isolated myocytes, Bendavia protection appeared to be mediated by lowered reactive oxygen species-mediated cell death during reoxygenation.

    In plain wordsIn cells, Bendavia seemed to protect heart muscle cells by lowering cell death caused by reactive oxygen species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseROS-mediated cell death during reoxygenation
    Study

    n: not reported in source

    Isolated myocytes
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This protection appeared to be mediated by lowered reactive oxygen species-mediated cell death during reoxygenation, associated with sustainment of mitochondrial membrane potential in Bendavia-treated myocytes.
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.
  8. 08LabIn vitro (cells)Mechanism

    In isolated myocytes, Bendavia treatment was associated with sustained mitochondrial membrane potential.

    In plain wordsIn cells, Bendavia treatment was linked to a steady mitochondrial membrane potential in heart muscle cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential during reoxygenation
    Study

    n: not reported in source

    Isolated myocytes
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    associated with sustainment of mitochondrial membrane potential in Bendavia-treated myocytes.
    1 context sentence
    Summary · context
    We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Peptides), across a spectrum of experimental cardiac ischemia/reperfusion models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.